CEPI - IABS

Cross learning experience human and animal vaccine licensure based on technology platforms

Palais de l'Académie Royale des Sciences
Rue Ducale, 1
B 1000 Bruxelles

Jayanthi Wolf, Ph.D.
Executive Director, Global Regulatory Affairs
Merck, Sharp & Dohme (MSD)
351 North Sumneytown Pike
North Wales, PA, 19454, USA
Tel: +1-267-305-5883
Fax: +1-267-305-6407
e-mail: jayanthi.wolf@merck.com

Dr. Jayanthi Wolf has more than eighteen years of experience in the development of vaccines and biotherapeutics. She is currently an Executive Director in the department of Global Regulatory Affairs and Clinical Safety at Merck (known as MSD outside the United States and Canada), where she provides regulatory leadership for project teams by developing and implementing global regulatory strategies for Infectious Disease/Vaccine programs. She also manages a team of global regulatory liaisons supporting vaccine programs. Her expertise is in the development of vaccines for emerging infectious diseases, including an Ebola vaccine (ERVEBO™), which has been approved by European Medicines Agency and the United States Food and Drug Administration and pre-qualified by the World Health Organization.

Prior to working in regulatory affairs, Dr. Wolf held various scientific and managerial positions in Safety Assessment and Bioprocess Development. She has contributed to the discovery, development and licensure of several vaccines and biological products. Dr. Wolf earned her Ph.D. degree in Molecular Biology and Immunology from Princeton University prior to joining MSD in 2001. She is a member of the Regulatory Affairs Professional Society, Society of Toxicology, and the Biotechnology Innovation Organization (BIO) Vaccines Regulatory Affairs Committee and BIO-Safe's Special Biologics Expert Working Group (vaccines, blood products, cell and gene therapies).